DJIA 18,203.37 -85.26 -0.47%
NASDAQ 4,979.90 -28.20 -0.56%
S&P 500 2,107.78 -9.61 -0.45%
market minute promo

4.57 0.18 (4.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

THLD $4.57 4.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.57
Previous Close $4.39
Daily Range $4.35 - $4.69
52-Week Range $2.58 - $5.58
Market Cap $286.8M
P/E Ratio -8.78
Dividend (Yield) $0.00 (0.0%)
Volume 1,160,627
Average Daily Volume 631,876
Current FY EPS -$0.46

Sector

Healthcare

Industry

Drug Makers

THRESHOLD PHARMACEUTICALS, INC. (THLD) Description

A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. Website: http://www.thresholdpharm.com/

News & Commentary

In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer

We know chemotherapy kills cancer cells, but it's also an indiscriminate killer of healthy cells. According to a new study released this past week, an entirely new treatment pathway could eliminate a significant portion of healthy cell death.

Mid-Day Market Update: Starwood Hotels Jumps Following CEO Resignation; CoStar Group Shares Slide

Threshold Pharmaceuticals Raises Cash - An Inside Look At The Deal

Health Care Sector Update for 02/12/2015: PLX, THLD, ACOR

Did Researchers Just Discover the Cause of Pancreatic Cancer?

Pancreatic cancer is the fourth-leading cause of cancer-related death, but researchers may have moved one step closer to discovering a cure this past week.

Twitter's Favorite Biotech and Pharma Stocks

Consensus? We don't need no stinking consensus!

Health Care Sector Update for 11/17/2014: INO, THLD, AZN

US Futures Barely Higher Closer to Open; Alibaba Surpasses $8 Bln in Sales on Singles' Day Shopping

US Futures Barely Higher Closer to Open; Alibaba Surpasses $8 Bln in Sales on Singles' Day Shopping Day

Threshold Pharmaceuticals Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previo

Threshold Pharmaceuticals Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma

Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented

Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented At The 2014 ASH Annual Meeting

See More THLD News...

THLD's Top Competitors

THLD $4.57 (4.10%)
Current stock: THLD
AMGN $158.56 (-0.67%)
Current stock: AMGN
GILD $102.79 (-1.00%)
Current stock: GILD
BIIB $412.79 (-0.72%)
Current stock: BIIB